Related Experiment Video
Updated: Jun 11, 2025
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
1.7K
State-of-Art Therapeutics in IgA Nephropathy
Mohit Mathur1, Manisha Sahay2, Brian J G Pereira1
1Visterra, Inc., Waltham, MA, USA.
Indian Journal of Nephrology
|October 7, 2024
Summary
Immunoglobulin-A nephropathy (IgAN) is a common kidney disease. New treatments targeting its causes are emerging, offering hope beyond supportive care for patients with IgAN.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Immunoglobulin-A nephropathy (IgAN) is the leading cause of primary glomerulonephritis globally.
- A significant percentage of IgAN patients develop end-stage kidney disease (ESKD).
- Elevated galactose-deficient IgA1 (Gd-IgA1) drives immune complex deposition and kidney damage in IgAN.
Purpose of the Study:
- To review the current understanding of IgAN pathology and therapeutic landscape.
- To highlight emerging treatments targeting specific IgAN pathogenic mechanisms.
- To discuss the evolving standards of care for IgAN.
Main Methods:
- Literature review of IgAN pathogenesis and clinical trials.
- Analysis of current and investigational therapeutic strategies.
- Discussion of recent regulatory advancements, including surrogate endpoints.
Main Results:
- Supportive care with RAS inhibitors and SGLT2 inhibitors are current mainstays.
- Targeted-release budesonide and sparsentan have gained accelerated approval.
- Investigational therapies target Gd-IgA1 production (APRIL/BAFF inhibitors) and complement pathways.
Conclusions:
- The therapeutic landscape for IgAN is rapidly evolving with novel targeted treatments.
- Personalized medicine approaches are needed to address diverse IgAN pathologies.
- Updated treatment guidelines and standards of care are essential as new therapies emerge.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
8
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
8
01:28Chronic Kidney Disease III: Interprofessional Care
2
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
2
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
01:24Nephrotic Syndrome III : Nursing Management
2
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
2
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117